PGX on trackFirst PGX product could be approved by Health Canada and available for commercial sale by year-end which is only about 6 months away. With the first precedent setting product approval for PGX and small-scale commercial production achieved as Natex expects to commission the 10X scale-up next quarter what could PGX deals look like now? The 10X scale-up with industry leader Natex is the decision point for mass industrialization of PGX. With the added capital and capability from the AEZS as well as tax-loss carryforwards CZO is in a stronger positon than ever to execute on PGX deals. A comprehensive scientific article was also recently submitted to the Biomaterials scientific journal for PGX-YBG/fibrosis.
Last news release:
"We are very pleased with progress made in the development of new products and technologies such as the... very well-advanced 50L scale-up of the PGX Technology which will enable the development and production of yeast beta glucan as an immune modulator."
"Edmonton Main Facility - PGX Scale-Up 50 Liters Vessel: This project is almost completed. Three trial runs of yeast beta glucan have been performed as part of the last commissioning phase. Given that the Edmonton site license is for natural products, yeast beta glucan produced from this facility will be offered as a nutraceutical. Subject to approval by Health Canada, this product could be launched by end of 2024."
"Natex Facility, Austria - PGX Scale-Up 100 Liters Vessel: The project is on schedule. PGX pressure vessel design is 100% completed. Initial safety and regulatory risk assessment has also been completed. Commissioning is expected to be completed by end of Q3 2024."